Kraig Biocraft Laboratories Inc   (KBLB)
Other Ticker:  
Price: $0.0940 $0.00 -1.053%
Day's High: $0.1 Week Perf: 38.24 %
Day's Low: $ 0.08 30 Day Perf: 132.1 %
Volume (M): 4,095 52 Wk High: $ 0.10
Volume (M$): $ 385 52 Wk Avg: $0.04
Open: $0.09 52 Wk Low: $0.03

 Market Capitalization (Millions $) 97
 Shares Outstanding (Millions) 1,033
 Employees 5
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -3
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Kraig Biocraft Laboratories Inc

Kraig Biocraft Laboratories, Inc. is a corporation organized under the laws of Wyoming on April 25, 2006. We were organized to develop high strength fibers using recombinant DNA technology, for commercial applications in both the specialty fiber and technical textile industries. Specialty fibers are engineered for specific uses that require exceptional strength, flexibility, heat resistance and/or chemical resistance. The specialty fiber market is exemplified by two synthetic fiber products: aramid fibers and ultra-high molecular weight polyethylene fiber. The technical textile industry involves products for both industrial and consumer products, such as filtration fabrics, medical textiles (e.g., sutures and artificial ligaments), safety and protective clothing and fabrics used in military and aerospace applications (e.g., high-strength composite materials).

While scientists have been able to replicate the proteins that are the building blocks of spider silk, the technological barrier that has stymied production until now has been the inability to form these proteins into a fiber with the desired mechanical characteristics and to do so in a cost effective manner.

We have licensed the right to use the patented genetic sequences and genetic engineering technology developed in university laboratories. The Company has been working collaboratively with university laboratories to develop fibers with the mechanical characteristics of spider silk. We are applying this proprietary genetic engineering technology to domesticated silkworms, which are already the most efficient commercial producers of silk.

Our technology builds upon the unique advantages of the domesticated silkworm for this application. The silkworm is ideally suited to produce recombinant protein fiber because it is already an efficient commercial and industrial producer of protein based polymers. Forty percent (40%) of the caterpillars’ weight is devoted to the silk glands. The silk glands produce large volumes of protein, called fibroin, which are then spun into a composite protein thread (silk).

We are working to use our genetic engineering technology to create recombinant silk polymers. On September 29, 2010, we jointly announced with the University of Notre Dame the success of our collaborative research with Notre Dame in creating approximately twenty different strains of transgenic silkworm which produce recombinant silk polymers. In April 2011, we entered into a licensing agreement with Sigma-Aldrich which provides us the use of Sigma-Aldrich’s zinc finger technology to accelerate and enhance our product development.

A part of our intellectual property portfolio is the exclusive right to use certain patented spider silk gene sequences in silkworm. Under the Exclusive License Agreement with the University of Wyoming, we have obtained certain exclusive rights to use numerous genetic sequences which are the subject of US patents.

The introduction of the gene sequence, in the manner employed by us, results in a germline transformation and is therefore self-perpetuating. This technology is in essence a protein expression platform which has other potential applications including diagnostics and pharmaceutical production.

   Company Address: 2723 South State St. Suite 150 Ann Arbor 48104 MI
   Company Phone Number: 619-8066   Stock Exchange / Ticker: KBLB
   KBLB is expected to report next financial results on March 28, 2024.

Customers recorded net loss Customers recorded net loss

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
AVNT        3.06% 
• View Complete Report

Kraig Biocraft Laboratories Inc

Revolutionizing the Industry: Chemical Manufacturing Giant Achieves Extraordinary $0.049196 Million Revenue in Q3 2023 Financial Report

Kraig Biocraft Laboratories Inc (KBLB) is a biotechnology company that specializes in genetic engineering and developing innovative materials using spider silk. With a focus on commercializing spider silk technologies, the company aims to create stronger and more versatile materials for various industrial applications.
In the fiscal time-frame from July to September 2023, Kraig Biocraft Laboratories Inc reported a revenue of $0.049196 million. While this might seem relatively low, it is noteworthy considering the company's focus on research and development, which often generates revenue in the later stages of product development.

Kraig Biocraft Laboratories Inc

Kraig Biocraft Laboratories Inc Demonstrates Steady Sales with Revenue of $0.022638 Million in Q2 2023 Earnings Season

Kraig Biocraft Laboratories Inc, a prominent player in the Chemical Manufacturing industry, has recently released its financial results for the second quarter of the 2023 earnings season. The company reported a revenue of $0.022638 million during this period, showcasing its ability to generate consistent sales and maintain a steady market position.
However, these financial results also indicate a slight decline in net deficit compared to the same reporting period last year. Kraig Biocraft Laboratories Inc posted a net deficit of $-0.589 million, which is a modest improvement from the $-1.038 million deficit recorded in the corresponding period a year ago. While this may be perceived by some as a negative outcome, it is essential to consider the broader context in order to form a more comprehensive analysis of the company's financial health.
The Chemical Manufacturing industry is a complex and often volatile sector. Companies operating within it face numerous challenges, such as fluctuating demand, evolving regulations, and intense competition. Against this backdrop, Kraig Biocraft Laboratories Inc's ability to reduce its net deficit and limit losses should be acknowledged as a positive achievement. It reflects the company's efforts to streamline operations, control costs, and find ways to improve its bottom line.

Kraig Biocraft Laboratories Inc

Kraig Biocraft Laboratories Inc Outshines Expectations with Revenue Growth in Q1 2023

Chemical Manufacturing company has reported a revenue of $0.004269 million in the financial time-frame ending March 31 2023. This is a modest growth in revenue compared to the previous reporting period. The company's financials have been on an upward trend in recent times.
On the other hand, Kraig Biocraft Laboratories Inc has reported a net deficit of $-0.567 million, which is a significant improvement compared to a deficit of $-1.047 million in the same reporting period a year ago. This indicates that the company has made significant efforts to improve its financials and cut down on losses.


Kraig Biocraft Laboratories Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com